Dexcom DXCM US has added +21.97% over the last 5 trading days. In fact most of those gains have been delivered since we highlighted the stock on Monday 18th May. Over the same 5-day period the S&P 500 Healthcare sector has lost -0.07% so we have certainly seen some alpha generated in the name.
The question some of you may be asking is what should I do now? The answer to that depends on why you bought it in the first place.
If you were in for a trade powered by improving sentiment toward the stock, them taking some profits here would make sense. However it might be worth waiting to see how the US opens, because rumours persist that an end to the Iran war is in sight.
If, however, you bought Dexcom because you thought Elliot Management would wring out substantial shareholder value and efficiencies then I would suggest staying put. Let’s not forget that the stock traded up to $164.86 in 2021.
In the near term. resistance around $90.00 takes my eye for example.

DXCM US is trading at $74.80 up by +3.29% on a day when broader US equity markets are weaker. CFDS on the S&P 500 in London show the index down by more than – 1.00% as I type. $74.80 compares very favourable with the levels they were when I wrote about them back in mid-May.
There was broker comment yesterday when Stifel raised their price target by $5.00 and ten company announced a bolt on acquisition with the purchase of wellness tracking company Nutrisense for an undisclosed fee.
According the Massdevice website:
“Nutrisense’s offerings enable Dexcom to incorporate access to registered dietitians, personalized nutrition guidance and behavior-change support.”